Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Takeda Pharmaceutical Ltd ADR
(NY:
TAK
)
13.25
UNCHANGED
Streaming Delayed Price
Updated: 7:00 PM EDT, Jul 10, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Takeda Pharmaceutical Ltd ADR
< Previous
1
2
3
4
5
6
7
8
9
...
16
17
Next >
NeurAxis: Should You Buy This IPO?
February 08, 2023
As NeurAxis is ready to launch its IPO, we take a closer look to see if investors should be buying into the hype.
Via
Talk Markets
NeurAxis IPO Sets Stage To Take On Irritable Bowel Syndrome With A Non-Surgical Solution
February 06, 2023
As NeurAxis gears up for its upcoming IPO, we take a deep dive into the company to see if it's worth adding to your investment portfolio.
Via
Talk Markets
U.S. FDA Approves Takeda’s TAKHZYRO® (lanadelumab-flyo) to Prevent Hereditary Angioedema (HAE) Attacks in Children 2 Years of Age and Older
February 03, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Reports 13% Fall In Nine Month Operating Profit, Keeps Annual Guidance Unchanged
February 02, 2023
Via
Benzinga
Current Report: Takeda Pharmaceutical (TAK)
January 23, 2023
In the past year, Takeda’s share price increased by $1.73, or about 12%.
Via
Talk Markets
HUTCHMED Out Licenses Fruquintinib To Takeda Outside China
January 23, 2023
Via
Benzinga
A Bullish Sign Appears On Takeda Pharmaceutical's Chart
December 28, 2022
Via
Benzinga
Takeda Reinforces Long-term Growth Through Pipeline Advancement and Two Targeted Acquisitions; Delivers Another Strong Quarter in FY2022 Q3
February 02, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
7 Sorry Dividend Stocks to Sell in February Before It’s Too Late
January 30, 2023
These dividend stocks to sell have weak underlying fundamentals, offering little upside potential ahead for investors.
Via
InvestorPlace
Week In Review: HutchMed Announces $1.1 Billion Deal With Takeda For Colorectal Cancer Drug
January 28, 2023
Shanghai’s HutchMed out-licensed global rights for a colorectal cancer therapy to Japan’s Takeda in a deal worth up to $1.13 billion, including $400 million upfront. In addition to the $1.13 billion,...
Via
Talk Markets
Finch Therapeutics Halts Work On Its Only Clinical Stage Asset, Cuts 95% Of Workforce
January 24, 2023
Via
Benzinga
Takeda To Add Mid-Stage Autoimmune Disease Candidate For $4B
December 13, 2022
Via
Benzinga
Takeda's Dengue Vaccine Candidate Under FDA Priority Review
November 23, 2022
Via
Benzinga
HUTCHMED Announces License to Takeda to Develop and Commercialize Fruquintinib Outside China
January 23, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
Takeda To Acquire Exclusive Worldwide (ex-China) License of HUTCHMED’s Fruquintinib, a Highly Selective, Oral VEGFR1/2/3 Tyrosine Kinase Inhibitor
January 23, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Named Global Top Employer for Sixth Consecutive Year
January 16, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Week In Review: Qitan Raises $101 Million For Nanopore Sequencing Devices
January 14, 2023
Qitan Technology, a Chengdu nanopore sequencing company, completed a $101 million Series C round to support its commercialized nanopore devices. Meanwhile, Japan’s Takeda was approved to launch...
Via
Talk Markets
Takeda’s EXKIVITY® (mobocertinib) Receives Approval from the NMPA of China, Becoming the First and Only Therapy Available for Patients with EGFR Exon20 Insertion+ NSCLC
January 11, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Arrowhead Pharmaceuticals Reports Underwhelming Data From Inherited Disease Study
January 09, 2023
Via
Benzinga
Arrowhead and Takeda Announce Topline Results from SEQUOIA Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
January 09, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
CRISPR, Genetics And AI — Why 2023 Could Be The Year For Biotech Stocks
January 06, 2023
Genetic medicine is a top theme now for biotech stocks. Other trends are heating up too.
Via
Investor's Business Daily
Takeda Announces Favorable Phase 3 Safety and Efficacy Results of TAK-755 as Compared to Standard of Care in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
January 05, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Analyst Bullish On Theseus Pharma's Platform For Gastric Cancer Therapies
December 14, 2022
Via
Benzinga
Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858 From Nimbus Therapeutics
December 13, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Exelixis' Cabometyx/Tecentriq Combo Misses Overall Survival Goal In Lung Cancer Setting
December 09, 2022
Exelixis Inc (NASDAQ: EXEL) announced that the CONTACT-01 study
Via
Benzinga
Takeda to Present Data at 64th American Society of Hematology (ASH) Annual Meeting, Demonstrating Commitment to Patients with Hematologic Cancers and Other Blood Diseases
December 09, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda’s QDENGA®▼ (Dengue Tetravalent Vaccine [Live, Attenuated]) Approved for Use in European Union
December 08, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Global pharma giants partner Singapore researchers to boost innovation in biologics and vaccines manufacturing
December 06, 2022
From
Singapore Economic Development Board (EDB)A*STAR
Via
ACN Newswire
Are Tech Layoffs Going to Be a Headache for Alexandria Real Estate Equities?
November 30, 2022
Tech layoffs are in the news, but life sciences companies seem to be doing better.
Via
The Motley Fool
Arrowhead Pharmaceuticals Surges After Hinting At A Midstage Win In Liver Disease
November 29, 2022
The company says it plans soon to present Phase 2 results and its Phase 3 study design.
Via
Investor's Business Daily
< Previous
1
2
3
4
5
6
7
8
9
...
16
17
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.